Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Amoxicillin + clarithromycin is a combination of two antibiotics used primarily as part of multi-drug regimens to eradicate *Helicobacter pylori* (H. pylori) infection, which is associated with peptic ulcer disease. Amoxicillin is a penicillin-class antibiotic that kills bacteria by inhibiting cell wall synthesis, while clarithromycin is a macrolide antibiotic that inhibits bacterial protein synthesis. When used together, often in combination with a proton pump inhibitor (PPI) such as omeprazole or lansoprazole, they act synergistically to eliminate H. pylori and reduce the risk of ulcer recurrence[1][5][8]. Both drugs are small molecule antibiotics.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Amoxicillin + Clarithromycin.